Insulin resistance in a large cohort of women with polycystic ovary syndrome: a comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
STUDY QUESTION: Could surrogate indexes identify insulin resistant individuals among women with polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: Surrogate indexes may be able to rule in, but not rule out, insulin resistance in women with PCOS. WHAT IS KNOWN ALREADY: Insulin resistance is a typical finding of women with PCOS and most clinical information on this issue is based upon surrogate indexes of insulin resistance. However, data on the performance of these indexes in PCOS women are very limited. STUDY DESIGN SIZE, DURATION: A retrospective analysis of 406 women referred to our outpatient clinic for hyperandrogenism and/or menstrual dysfunction and submitted to hyperinsulinemic euglycaemic clamp between 1998 and 2015. PARTICIPANTS/MATERIALS, SETTING, METHODS: In total, 375 of these women had PCOS by the Rotterdam criteria and were included in the study. Six surrogate indexes of insulin sensitivity were calculated from glucose and insulin levels, either at fasting (homeostasis model assessment (HOMA), glucose/insulin (G/I) ratio and quantitative insulin sensitivity check index (QUICKI)) or after oral glucose load (Gutt, Stumvoll0-120 and Matsuda). MAIN RESULTS AND THE ROLE OF CHANCE: Overall, insulin resistance, as identified by the M-clamp value, was found in 74.9% of these women. The percentage was 59.3% in normal-weight vs 77.5% in overweight and 93.9% in obese subjects. All surrogate indexes were highly correlated with the M-clamp values. However, their ability to identify insulin resistant individuals was limited, in terms of sensitivity and especially in normal-weight subjects. ROC analysis showed similar performances of these indexes (AUC values 0.782-0.817). LIMITATIONS REASONS FOR CAUTION: Potential referral bias of PCOS patients may have caused overestimation of the prevalence of insulin resistance in these women. WIDER IMPLICATIONS OF THE FINDINGS: By using surrogate indexes many subjects with PCOS may be erroneously diagnosed as insulin sensitive, especially among normal-weight women. These indexes can be used to rule in, but not rule out, insulin resistance in PCOS. STUDY FUNDING/COMPETING INTEREST(S): Academic grants to P. Moghetti from the University of Verona. All authors declare no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“with nearly 75% of individuals with PCOS estimated to have some degree of insulin resistance [27].”
From Moving beyond Weight: A Narrative Review of the Dietary and Lifestyle Management for Reducing Cardiometabolic Risk in Polycystic Ovary Syndrome (PCOS) (2023) · cites this paper as [27]
In the citing paper
“Insulin resistance appears to be a large driver of these risk factors”
From Moving beyond Weight: A Narrative Review of the Dietary and Lifestyle Management for Reducing Cardiometabolic Risk in Polycystic Ovary Syndrome (PCOS) (2023) · cites this paper as [27]
In the citing paper
“In actual fact, they are more valuable in ruling in rather than ruling out insulin resistance in PCOS, especially among normal weight women [43].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [43]
In the citing paper
“In PCOS, IR is present in obese and overweight patients, as well as in those of normal weight, although in the latter group, with a lower frequency (59.3% in normal weight vs. 77.5% in overweight and 93.9% in obese patients) [33].”
From The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome (2022) · cites this paper as [33]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860 · cited 1×
“Diagnosis of metabolic syndrome was carried out using the 2009 joint criteria by the International Diabetes Federation (IDF) and other Societies (Alberti et al., 2009).”
Method(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425 · cited 1×
“Glucose disposal rate during the steady-state period of the clamp (M-clamp) was calculated with standard formula (DeFronzo et al., 1979).”
MethodMatsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 1×
“…in other clinical conditions, suggested that surrogate indexes derived from the OGTT could perform better, as compared with those obtained from fasting values (Matsuda and DeFronzo, 1999; Gutt et al., 2000; Stumvoll et al., 2001), although the amount of additional information may indeed be limited.”
BackgroundKatz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,931
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456 · cited 1×
“Because muscle is responsible for most insulin-induced glucose metabolism (DeFronzo, 1988), glucose disposal data were expressed per fat-free mass (mg/kg FFMmin).”
BackgroundMen at risk: occupation and male infertility
Claman, P. (2004) · Fertility and Sterility · doi:10.1016/s0015-0282(03)01188-9 · Cited by 2,387
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947 · cited 1×
“Second, insulin resistance plays a crucial role in the pathogenesis of PCOS itself (Diamanti-Kandarakis and Dunaif, 2012).”
BackgroundHirsutism: Implications, etiology, and management
Hatch, R., Rosenfield, R. L., Kim, M. H., & Tredway, D. (1981) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(81)90746-8 · Cited by 1,014 · cited 2×
“Clinical hyperandrogenism was defined by the presence of hirsutism (modified Ferriman–Gallwey score ≥8) (Hatch et al., 1981) and/or acne and/or alopecia; biochemical hyperandrogenism was defined by increased levels of at least one serum androgen (total or free testosterone, androstenedione or dehydroepiandrosterone su…”
Background
Cited by
Zhao, H., Zhang, J., Cheng, X., Nie, X., & He, B. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-022-01091-0 · Cited by 408
Armanini, D., Boscaro, M., Bordin, L., & Sabbadin, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084110 · Cited by 324
“In actual fact, they are more valuable in ruling in rather than ruling out insulin resistance in PCOS, especially among normal weight women [43].”
BackgroundCaprio, M., Infante, M., Moriconi, E., Armani, A., Fabbri, A., Mantovani, G., Mariani, S., Lubrano, C., Poggiogalle, E., Migliaccio, S., et al. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01061-2 · Cited by 283
Insulin resistance and PCOS: chicken or egg?
Moghetti, P., & Tosi, F. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01351-0 · Cited by 209
Self-citationPolycystic ovary syndrome as a metabolic disease
Helvaci, N., & Yildiz, B. O. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01057-w · Cited by 188
Role of insulin and insulin resistance in androgen excess disorders
Unluhizarci, K., Karaca, Z., & Kelestimur, F. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i5.616 · Cited by 184
Exercise Interventions in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis
Patten, R. K., Boyle, R. A., Moholdt, T., Kiel, I., Hopkins, W. G., Harrison, C. L., & Stepto, N. K. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00606 · Cited by 163
“Although not currently included in the diagnostic criteria, insulin resistance determined from insulin clamps is prevalent in 56–95% of women with PCOS (Stepto et al., 2013; Tosi et al., 2017; Li et al., 2019).”
Bednarz, K., Kowalczyk, K., Cwynar, M., Czapla, D., Czarkowski, W., Kmita, D., Nowak, A., & Madej, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084334 · Cited by 148
Markers of insulin resistance in Polycystic ovary syndrome women: An update
Amisi, C. A. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i3.129 · Cited by 130
Di Lorenzo, M., Cacciapuoti, N., Lonardo, M. S., Nasti, G., Gautiero, C., Belfiore, A., Guida, B., & Chiurazzi, M. (2023) · Current Nutrition Reports · doi:10.1007/s13668-023-00479-8 · Cited by 108
Wen, Q., Hu, M., Lai, M., Li, J., Hu, Z., Quan, K., Liu, J., Liu, H., Meng, Y., Wang, S., et al. (2022) · Human Reproduction · doi:10.1093/humrep/deab272 · Cited by 93
“Approximately 50–75% of women with PCOS also suffer from insulin resistance (IR) (Dunaif, 1997; Ovalle and Azziz, 2002; Carmina and Lobo, 2004; Tosi et al. , 2017).”
Dietary Interventions: A Promising Treatment for Polycystic Ovary Syndrome
Che, X., Chen, Z., Liu, M., & Mo, Z. (2021) · Annals of Nutrition and Metabolism · doi:10.1159/000519302 · Cited by 87
Usselman, C. W., Yarovinsky, T. O., Steele, F. E., Leone, C. A., Taylor, H. S., Bender, J. R., & Stachenfeld, N. S. (2019) · The Journal of Physiology · doi:10.1113/jp277756 · Cited by 86
“Fasting and OGTT estimates of IR can be limited in ruling out IR in lean insulin-sensitive AE-PCOS (Tosi et al. 2017), so we used especially stringent standards to define this group.”
MethodDobbie, L. J., Pittam, B., Zhao, S. S., Alam, U., Hydes, T., Barber, T. M., & Cuthbertson, D. J. (2023) · Human Reproduction · doi:10.1093/humrep/dead053 · Cited by 95
“Approximately 75% of people with PCOS have insulin resistance (Tosi et al. , 2017).”
Emanuel, R. H. K., Roberts, J., Docherty, P. D., Lunt, H., Campbell, R. E., & Möller, K. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1017468 · Cited by 100
Depression in polycystic ovary syndrome: Focusing on pathogenesis and treatment
Xing, L., Xu, J., Wei, Y., Chen, Y., Zhuang, H., Tang, W., Yu, S., Zhang, J., Yin, G., Wang, R., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1001484 · Cited by 91
Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS
Houston, E. J., & Templeman, N. M. (2025) · Journal of Endocrinology · doi:10.1530/joe-24-0269 · Cited by 109
Effect and mechanism of berberine against polycystic ovary syndrome
Zhang, S., Zhou, J., Gober, H.-J., Leung, W. T., & Wang, L. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111468 · Cited by 82
Subclinical cardiovascular disease and polycystic ovary syndrome
Gomez, J. M. D., VanHise, K., Stachenfeld, N. S., Chan, J. L., Merz, C. N. B., & SHUFELT, C. L. (2022) · Fertility and Sterility · doi:10.1016/j.fertnstert.2022.02.028 · Cited by 86
Zhang, S., Tu, H., Yao, J., Le, J., Jiang, Z., Tang, Q., Zhang, R., Huo, P., & Lei, X. (2020) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-020-00613-z · Cited by 70
“Currently, high insulin resistance in PCOS patients is a hot topic in the field of reproductive endocrinology and insulin resistance appears to be the fundamental key factor within the pathophysiology of PCOS [13].”
BackgroundNutritional guidelines for the management of insulin resistance
Muscogiuri, G., Barrea, L., Caprio, M., Ceriani, F., Chavez, A. O., El Ghoch, M., Frias-Toral, E., Mehta, R. J., Mendez, V., Paschou, S. A., et al. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1908223 · Cited by 63
“…PCOS, and it can be present independently of obesity, having a prevalence up to 74.9% in women with PCOS according to M-clamp value (euglycemic hyperinsulinemic clamp), 59.3% of normal-weight patients vs. 77.5% in overweight and 93.9% of the subjects with obesity (Tosi, Bonora, and Moghetti 2017).”
BackgroundInfluentialAl-Kuraishy, H. M., Al-Gareeb, A. I., Waheed, H. J., & Al-Maiahy, T. J. (2018) · Journal of Advanced Pharmaceutical Technology amp Research · doi:10.4103/japtr.japtr_273_18 · Cited by 61
“QUICKI = + 1 log( / log( / ) fastinginsulin1⁄4U mL fasting glucose mg dL [14]”
Patten, R. K., McIlvenna, L. C., Levinger, I., GARNHAM, A. P., Shorakae, S., Parker, A. G., McAinch, A. J., Rodgers, R. J., Hiam, D., Moreno‐Asso, A., et al. (2022) · Human Reproduction · doi:10.1093/humrep/deac047 · Cited by 75
Patton, L., Ricolfi, L., Bortolon, M., Gabriele, G., Zolesio, P., Cione, E., & Cannataro, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031599 · Cited by 67
“…Stumvoll 0–120, which was calculated from the blood glucose and insulin values detected with OGTT in basal conditions and 120 min after the glucose load considering the cut-off of 0.080 indicative of insulin resistance [35,36]: we noted a condition of insulin resistance in 7% of patients (10/141).”
MethodInfluentialVasukova, E. A., Zaikova, E. K., Kalinina, O., Gorelova, I. V., Pyanova, I., Bogatyreva, E., Vasilieva, E. Y., Grineva, E. N., & Popova, P. (2023) · Biomedicines · doi:10.3390/biomedicines11102791 · Cited by 67
“About 75% of women with PCOS have IR [2].”
BackgroundPolycystic ovary syndrome: A metabolic disorder with therapeutic opportunities
Zhang, Y., Chen, Z., & Zhao, H. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.08.002 · Cited by 66
Altered Ovarian Inositol Ratios May Account for Pathological Steroidogenesis in PCOS
Unfer, V., Dinicola, S., Laganà, A. S., & Bizzarri, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197157 · Cited by 50
“A typical PCOS phenotype is characterized by hyperandrogenism and ovarian dysfunctions; however, other frequent abnormalities, usually not included among the canonical diagnostic criteria, may be present [3].”
BackgroundEzeh, U., Ezeh, C., Pisarska, M. D., & Azziz, R. (2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.12.015 · Cited by 50
Sanchez-Garrido, M. A., Serrano-López, V., Ruíz-Pino, F., Vazquez, M. J., Rodríguez-Martín, A., Torres, E., Velasco, I., Rodríguez, A., Chicano‐Gálvez, E., Mora-Ortiz, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52898-y · Cited by 60
“2) As compared with the PNA model, the PWA one more closely resembles the classic phenotype of PCOS in humans because it displays overweight, impaired glucose homeostasis and anovulation.”
Lechner, K., Lechner, B., Crispin, A., Schwarz, P. E. H., & von Bibra, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-87266-z · Cited by 46
Polycystic Ovary Syndrome: Impact of Lipotoxicity on Metabolic and Reproductive Health
Brennan, K. M., Kroener, L. L., Chazenbalk, G. D., & Dumesic, D. A. (2019) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000661 · Cited by 48
Wang, R., Gu, Z., Wang, Y., Yin, X., Liu, W., Chen, W., Huang, Y., Wu, J., Yang, S., Feng, L., et al. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202206670 · Cited by 47
Hyperandrogenism and Cardiometabolic Risk in Pre- and Postmenopausal Women—What Is the Evidence?
Hirschberg, A. L. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad590 · Cited by 46
Pililis, S., Lampsas, S., Kountouri, A., Pliouta, L., Korakas, E., Livadas, S., Thymis, J., Peppa, Μ., Kalantaridou, S., Oikonomou, E. K., et al. (2024) · Medicina · doi:10.3390/medicina60101656 · Cited by 63
Insulin resistance, metabolic syndrome and polycystic ovaries: an intriguing conundrum
Prosperi, S., & Chiarelli, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1669716 · Cited by 72
“HOMA-IR has shown strong correlation with the euglycemic clamp and has been broadly used in studies of women with PCOS across various populations (59 – 61).”
Li, W., Chen, Q., Xie, Y., Hu, J., Yang, S., & Lin, M. (2018) · Clinical Endocrinology · doi:10.1111/cen.13860 · Cited by 42
Huang‐Doran, I., Kinzer, A. B., Jimenez‐Liñan, M., Thackray, K., Harris, J., Adams, C. L., de Kerdanet, M., Stears, A. J., O’Rahilly, S., Savage, D. B., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab275 · Cited by 42
“IR is reported in up to 70% of cases of “common” PCOS (58, 59) but the direction of causality is debated.”
Pandurevic, S., Mancini, I., Mitselman, D., Magagnoli, M., Teglia, R., Fazzeri, R., Dionese, P., Cecchetti, C., Caprio, M., Moretti, C., et al. (2023) · Endocrine Connections · doi:10.1530/ec-22-0536 · Cited by 36
Zheng, R., Shen, H., Li, J., Zhao, J., Lu, L., Hu, M., Lin, Z., Ma, H., Tan, H., Hu, M., et al. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115824 · Cited by 43
Ruan, X., Jing-hua, S., Gu, M., Wang, L., Wang, H., & Mueck, A. O. (2018) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-018-4762-0 · Cited by 35
“Insulin resistance appears to be the fundamental key factor within the pathophysiology of PCOS [19, 20].”
BackgroundBrzozowska, M. M., Isaacs, M., Bliuc, D., Baldock, P. A. J., Eisman, J. A., White, C., & Greenfield, J. R. (2023) · Scientific Reports · doi:10.1038/s41598-023-33317-6 · Cited by 38
Xie, Y., Xiao, L. Y., & Li, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.701590 · Cited by 39
Kim, J., Hwang, K. R., Oh, S. H., Chae, S. J., Yoon, S. H., & Choi, Y. M. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.06.035 · Cited by 37
Non-Coding RNAs as Potential Novel Biomarkers for Early Diagnosis of Hepatic Insulin Resistance
Pielok, A., & Marycz, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114182 · Cited by 31
“For example, in patients with polycystic ovary syndrome (PCOS), the aforementioned surrogate tests have presented a high positive predictive value (90–96%) but a low negative predictive value (36–45%); therefore, a number of subjects have remained unrecognized by any of these methods [19].”
BackgroundInsulin-Mediated Substrate Use in Women With Different Phenotypes of PCOS: the Role of Androgens
Tosi, F., Villani, M., Migazzi, M., Faccin, G., Garofalo, S., Fiers, T., Kaufman, J., Bonora, E., & Moghetti, P. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab380 · Cited by 33
Self-citationA PCOS Paradox: Does Inositol Therapy Find a Rationale in All the Different Phenotypes?
Unfer, V., Dinicola, S., & Russo, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076213 · Cited by 34
“Considering that the majority of women with PCOS exhibit insulin resistance (IR) [8,9] or other metabolic issues, including hyperinsulinemia, obesity, and diabetes, it seems”
BackgroundAcanthosis Nigricans: Pointer of Endocrine Entities
Radu, A.-M., Carşote, M., Dumitrașcu, M. C., & Şandru, F. (2022) · Diagnostics · doi:10.3390/diagnostics12102519 · Cited by 38
Lahooti, A., Westerveld, D., JOHNSON, K., Aneke-Nash, C. S., Baig, M. U., Akagbosu, C., Hanscom, M. H., Buckholz, A. P., Newberry, C. A., Herr, A., et al. (2024) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2024.12.017 · Cited by 31
Insights on the NF-κB system in polycystic ovary syndrome, attractive therapeutic targets
Tan, W., Zhang, J., Dai, F., Yang, D., Gu, R., Tang, L., Liu, H., & Cheng, Y. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04736-w · Cited by 34
“It was estimated that insulin resistance has been observed in 74.9% of PCOS patients [64].”
InfluentialBioinformatics searching of diagnostic markers and immune infiltration in polycystic ovary syndrome
Yao, X., & Wang, X. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.937309 · Cited by 26
McIlvenna, L. C., Patten, R. K., McAinch, A. J., Rodgers, R. J., Stepto, N. K., & Moreno‐Asso, A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.732338 · Cited by 21
Parker, J., Briden, L., & Gersh, F. L. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124021 · Cited by 40
Yang, T., Yang, Y., Zhang, Q., Liu, D., Liu, N., Li, Y., Yao, Z., Zhang, Y., Tian, F., Zhao, J., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.880518 · Cited by 22
Current treatment for polycystic ovary syndrome: focus on adolescence
Street, M. E., Cirillo, F., Catellani, C., Dauriz, M., Lazzeroni, P., Sartori, C., & Moghetti, P. (2020) · Minerva Pediatrics · doi:10.23736/s0026-4946.20.05861-2 · Cited by 21
Self-citationFulghesu, A. M., Piras, C., Dessì, A., Succu, C., Atzori, L., Pintus, R., Gentile, C., Angioni, S. L., & Fanos, V. (2021) · Metabolites · doi:10.3390/metabo11070437 · Cited by 20
“Nevertheless, recent studies suggest that hyperinsulinemia, due to increased β-cell secretory capacity, is a prominent feature in PCOS subjects independent from body weight, which drives levels of androgen excess in PCOS [16,28,31].”
BackgroundPustotina, O. A., Myers, S. H., Unfer, V., & Rasulova, I. (2024) · Gynecologic and Obstetric Investigation · doi:10.1159/000536163 · Cited by 24
“This is mirrored in patient populations, as 50 – 80% of women with PCOS are affected by IR [2, 3], 61% are overweight/obese [4], and > 50% suffer from type 2 diabetes mellitus and metabolic syndrome before the age of 40 [5].”
BackgroundAdipose-androgen crosstalk in polycystic ovary syndrome: mechanisms and therapeutic implications
Ni, M., Lei, H., Ye, T., & Wang, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1731179 · Cited by 27
Cussen, L., McDonnell, T., Miller, C., McIlroy, M., & O’Reilly, M. (2025) · Reproduction · doi:10.1530/rep-25-0102 · Cited by 22
Feng, J., Luo, R., Gao, J., Wang, Y., Cong, J., Ma, H., & Wu, X. (2025) · Clinical Endocrinology · doi:10.1111/cen.15252 · Cited by 19
“Epidemiological data derived from HIEC criteria [33, 34] demonstrate significant IR prevalence across BMI categories: 59.3% in nonobese, 77.5% in overweight, and 93.9% in obese PCOS patients.”
InfluentialHerbert, S., & Woolf, K. (2023) · Nutrients · doi:10.3390/nu15245069 · Cited by 15
“Insulin resistance appears to be a large driver of these risk factors, with nearly 75% of individuals with PCOS estimated to have some degree of insulin resistance [27].”
BackgroundVigna, L., Tirelli, A. S., Gaggini, M., Piazza, S. D., Tomaino, L., Turolo, S., Moroncini, G., Chatzianagnostou, K., Bamonti, F., & Vassalle, C. (2022) · Endocrine · doi:10.1007/s12020-022-03087-8 · Cited by 15
“Nonetheless, comparison studies suggest that there could be differences in the prevalence of insulin resistance detected by using different indirect indexes [8].”
BackgroundNon-cell autonomous mechanisms control mitochondrial gene dysregulation in polycystic ovary syndrome
Moreno‐Asso, A., Altıntaş, A., McIlvenna, L. C., Patten, R. K., Botella, J., McAinch, A. J., Rodgers, R. J., Barrès, R., & Stepto, N. K. (2021) · Journal of Molecular Endocrinology · doi:10.1530/jme-21-0212 · Cited by 16
“At the pathophysiological level, PCOS has a strong metabolic component with insulin resistance being present in 38–95% of women with PCOS (Moghetti et al. 2013, Stepto et al. 2013, Tosi et al. 2017).”
Li, Y., Wang, Y., Liu, H., Zhang, S., & Zhang, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1117996 · Cited by 19
Factors associated with body weight gain and insulin-resistance: a longitudinal study
Buscemi, C., Randazzo, C., Barile, A. M., Bo, S., Ponzo, V., Caldarella, R., Malavazos, A. E., Caruso, R., Colombrita, P., Lombardo, M., et al. (2024) · Nutrition and Diabetes · doi:10.1038/s41387-024-00283-5 · Cited by 19
“However, EHC has been previously shown to correlate well with HOMA-IR values [35]; it is not a simple technique to perform in large cohorts, and to our knowledge, there is a paucity of studies using this technique beyond the fi rst 6 months post weight loss bariatric surgery interventions [36, 37].”
Treatment with Myo-Inositol Does Not Improve the Clinical Features in All PCOS Phenotypes
Unfer, V., Russo, M., Aragona, C., Bilotta, G., Oliva, M. M., & Bizzarri, M. (2023) · Biomedicines · doi:10.3390/biomedicines11061759 · Cited by 18
“Data retrieved from the scientific literature indicate that about 75% of women with PCOS exhibit insulin resistance (IR) [28], or other endocrine and metabolic alterations such as hyperinsulinemia, diabetes, and obesity [29,30].”
BackgroundHoteit, B. H., Kotaich, J., Ftouni, H., Hazime, F., Safawi, A., Masri, R., & Marwani, M. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251383064 · Cited by 21
“29 It is defined as an impaired cellular response to insulin, caused by a defect in the insulin receptor-related signaling pathway, and is commonly associated with high visceral fat, persistent inflammation, and reactive oxygen species (ROS).”
Dahan, M. H., Abbasi, F., & Reaven, G. M. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01014-9 · Cited by 15
Huo, Y., Ji, S., Yang, H. J., Wu, W., Yu, L., Ren, Y., & Wang, F. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-2941 · Cited by 21
“It has been reported that about 70% of patients are insulin resistant (6,7).”
Little, P. J., Offermanns, S., Cho, H., Liu, Z., Yang, P., Su, Q., Wade, H., Yang, W., Kamato, D., Cohen, N. D., et al. (2026) · iNew Medicine · doi:10.1002/inm3.70028 · Cited by 27
Mosorin, M., Piltonen, T., Rantala, A. S., Kangasniemi, M. H., Korhonen, E., Bloigu, R., Tapanainen, J. S., & Morin-Papunen, L. C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082827 · Cited by 15
PCOS and Inositols – Advances and Lessons We are Learning. A Narrative Review
Lentini, G., Querqui, A., Monti, N., & Bizzarri, M. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s524718 · Cited by 20
“10 Overall, these considerations have prompted to reconsider the meaning of the syndrome, paving the way to a reinterpretation of the basic pathogenetic mechanisms as a key for establishing an appropriate, tailored treatment.”
Pandurevic, S., Bergamaschi, L., Pizzi, C., Patton, L., Rucci, P., Corzani, F., Cecchetti, C., Pelusi, C., Altieri, P., Vicennati, V., et al. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0725 · Cited by 12
“Low SHBG is a recognised feature of PCOS (38), particularly in 260 the presence of insulin resistance, which accompanies almost all obese PCOS women when measured by the 261 euglycaemic-hyperinsulinemic clamp (44,45).”
BackgroundKolnikaj, T. S., Herman, R., Janež, A., & Jensterle, M. (2022) · Life · doi:10.3390/life12111906 · Cited by 12
Wongwananuruk, T., Prasongvej, P., Chantrapanichkul, P., Indhavivadhana, S., Tanmahasamut, P., Rattanachaiyanont, M., Techatraisak, K., & Angsuwathana, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051452 · Cited by 14
“Notably, the cut-off value of HOMA-IR in an Italian study was lower, which may be attributed to variations in ethnicity, age, central obesity and BMI [14].”
Patton, L., Reverdito, V., Bellucci, A., Bortolon, M., Macrelli, A., & Ricolfi, L. (2025) · Clinics and Practice · doi:10.3390/clinpract15070128 · Cited by 15
“As a second method for the diagnosis of insulin resistance, the surrogate index called the Matsuda Index was used [40]; a value of less than 3.5 was considered diagnostic for insulin resistance [41].”
InfluentialStenberg, E., Rask, E., Szabó, É., Näslund, I., & Ottosson, J. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04599-w · Cited by 12
Modeling Obesity-Associated Ovarian Dysfunction in Drosophila
Liu, H., Li, J., Chang, X., He, F., & Ma, J. (2022) · Nutrients · doi:10.3390/nu14245365 · Cited by 13
“Meanwhile, around 50–75% of patients with PCOS are obese or have impaired insulin sensitivity [24,25], and obese females are at higher risk for fertility issues [26] and T2D [27].”
BackgroundEvans, A. T., Brink, H. V., Lim, J. S. W., Jarrett, B. Y., Lin, A., Lujan, M. E., & Hoeger, K. M. (2023) · Biomedicines · doi:10.3390/biomedicines11102763 · Cited by 15
“Blood glucose was measured on-site using a glucometer (Accu-chek Aviva, Roche, Basel, Switzerland), and values were used to calculate the homeostatic model assessment for insulin resistance (HOMA-IR; (Insulin 0hr * Glucose 0hr )/22.5) [20,21].”
MethodInfluentialMean platelet volume and polycystic ovary syndrome: a systematic review and meta-analysis
Li, L., Yu, J., & Zhou, Z. (2022) · Journal of International Medical Research · doi:10.1177/03000605211067316 · Cited by 12
“9% of obese women.(30) The degree of insulin resistance can, to some extent, reveal the severity of PCOS.”
BackgroundEmanuel, R. H. K., Docherty, P. D., Lunt, H., & Campbell, R. E. (2023) · JMIR Formative Research · doi:10.2196/44810 · Cited by 9
“Cross-sectional observational ChineseFastingEarly Follicular600Cai et al [30] Tosi et al [26] identify a potential referral bias Exploring how well insulin resisRetrospective analysis 97.1 % Caucasian (3.9% undeclared) (Italian Study) FastingNot Specified375Tosi et al [31] toward insulin resistant women.”
BackgroundResultInfluentialZhang, Z., Huo, P. F., Lei, X., Xue, H., Yang, X., Le, J., & Zhang, S. (2024) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2024.104750 · Cited by 10
Moghetti, P., Catellani, C., Sartori, C., Migazzi, M., Cirillo, F., Villani, M., Buia, V., Righi, B., Dauriz, M., Fiers, T., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02119-y · Cited by 9
Self-citationvan Helden, J., Evliyaoğlu, O., Küberl, A., & Weiskirchen, R. (2020) · Clinical Endocrinology · doi:10.1111/cen.14181 · Cited by 8
Risk factors for insulin resistance in midlife Singaporean women
Poromaa, I. S., Thu, W. P. P., Kramer, M. S., Logan, S. J. S., Cauley, J. A., & Yong, E. (2020) · Maturitas · doi:10.1016/j.maturitas.2020.04.003 · Cited by 10
Screening target genes for the treatment of PCOS via analysis of single-cell sequencing data
Lu, Z., Chen, C., Gao, Y., Li, Y., Zhao, X., Zhang, H., Wei, Q., Zeng, X., Li, Y., & Wan, M. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2136401 · Cited by 8
Unraveling PCOS therapies: Pharmacotherapeutic strategies and emerging therapeutic targets
Shirasath, K. R., Ahmed, N. Z., Kumar, P., Alam, S., Karwasra, R., Goyal, S. N., & Agrawal, Y. O. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156245 · Cited by 7
Yang, X., Liu, P., He, H., Qi, D., & Yan, L. (2024) · Molecular Human Reproduction · doi:10.1093/molehr/gaae005 · Cited by 10
Delphi consensus on the diagnostic criteria of polycystic ovary syndrome
Facchinetti, F., Gambineri, A., Aimaretti, G., Ferlin, A., Laganà, A. S., Moghetti, P., Oliva, M. M., Unfer, V., & Colao, A. A. L. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02533-4 · Cited by 10
“…glucose and insulin levels, are highly correlated with gold standard measures of insulin action, their ability in recognizing insulin resistant individuals is limited, particularly in terms of sensitivity, which may cause many subjects to be erroneous diagnosed as insulin sensitive [24].”
Self-citationTosi, F., Lando, M. G., Rosmini, F., Lucarini, F., Fiorio, V., Zanolin, M. E., Fiers, T., Kaufman, J., & Moghetti, P. (2025) · Human Reproduction · doi:10.1093/humrep/deaf114 · Cited by 7
Self-citationPhytotherapy in Polycystic Ovary Syndrome (PCOS) Management: A Systematic Review
Mohamed, S. S., Allam, A. T., Elalfy, A., El‐Shiekh, R. A., Reda, A. M., & Hafeez, M. S. A. E. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202500982 · Cited by 6
Šumarac-Dumanović, M., Stamenković-Pejković, D., Jeremić, D., Dumanović, J., Mandić, V., Žarković, M., & Micić, D. (2022) · International Journal of Endocrinology · doi:10.1155/2022/6630498 · Cited by 8
“In some previous studies [21, 22] it was showed that women with PCOS have intrinsic reduction in insulin sensitivity on euglycemichyperinsulinemic clamp and almost all obese women with PCOS have more serious IR than lean women with PCOS.”
ResultLi, Y., Zhang, S., & Zhang, C. (2024) · Journal of Ovarian Research · doi:10.1186/s13048-024-01491-4 · Cited by 7
Lambadiari, V., Pililis, S., Lampsas, S., Kountouri, A., Thymis, J., Pliouta, L., Peppa, Μ., Kalantaridou, S., Oikonomou, E. K., Siasos, G., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125488 · Cited by 7
“Insulin resistance is one of the key metabolic alterations in women with PCOS, affecting 65–95% of them, including predominantly overweight and obese women but also over half of normal-weight women [4].”
Endometrial receptivity and PCOS; endometrial gene expression specificities — literature review
Alebić, M. Š. (2022) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/j.ceog4902048 · Cited by 7
“Although insulin resistance and overweight/obesity are not included in the criteria for PCOS diagnosis, their prevalence is found to be as high as 75% and 54%, respectively [36].”
BackgroundPathophysiology of polycystic ovary syndrome
Raja, M. H. R., Javed, M. A., & Rehman, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87932-3.00013-x · Cited by 7
Asouri, S. A., Asemi, R., Aghadavod, E., & Jamilian, M. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001732 · Cited by 6
“Metabolic abnormalities including impaired glucose tolerance and dyslipidemia are frequent in this syndrome, and it was estimated that the action of insulin is lessened in about 75% of PCOS patients [8,9] .”
BackgroundHu, Z., Zeng, R., Tang, Y., Liao, Y., Li, T., & Qin, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1413068 · Cited by 8
Are menstrual disorders in adolescent girls related to metabolic disorders?
Foryś-Dworniczak, E., Baran, A., Dziurdzia, A., Jarosz-Wójcik, E., Matusik, P., Gawlik, A., Tomaszewski, R., & Zachurzok, A. (2023) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2023.125364 · Cited by 10
“However, due to its complexity it cannot be implemented on a routine basis [30].”
BackgroundTehrani, F. R., Fayaz, M., Firouzi, F., Azizi, F., Tohidi, M., & Behboudi‐Gandevani, S. (2025) · Endocrine Connections · doi:10.1530/ec-25-0266 · Cited by 5
“It is reported that it affects 65 – 95% of women with the syndrome, including the vast majority of overweight and obese women, as well as more than half of women of normal weight (36, 37, 38).”
Bai, Y., Liu, Y., Wang, Y., Liu, X., Wang, Y., Liu, H., Yi, H., Xu, C., & Zhang, F. (2024) · Reproductive Sciences · doi:10.1007/s43032-024-01631-7 · Cited by 6
Metadata
- Authors
- Tosi, F., Bonora, E., & Moghetti, P.
- Affiliations
- University of Verona (IT)
- Corresponding author
- Moghetti, Paolo
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-10-13
- Volume
- 32
- Issue
- 12
- Pages
- 2515-2521
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2763794285
- Cited by
- 163
- References
- 26
- Citations by year
- 2026: 26 · 2025: 28 · 2024: 21 · 2023: 24 · 2022: 27 · 2021: 16 · 2020: 10 · 2019: 6 · 2018: 5
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Human Reproduction (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Verona
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Keywords
- insulin resistance, polycystic ovary syndrome, hyperinsulinemic-euglycemic clamp, HOMA, QUICKI, Matsuda insulin sensitivity index, hyperandrogenism, menstrual disorders, obesity, normal-weight women, diagnostic accuracy, referral bias, hyperinsulinemia
- MeSH terms
- Adult, Body Weight, Female, Glucose Tolerance Test, Homeostasis, Humans, Hyperinsulinism, Insulin Resistance, Obesity, Phenotype, Polycystic Ovary Syndrome, Retrospective Studies, ROC Curve, Glucose Clamp Technique, Cohort Studies, Biomarkers, Hyperandrogenism, Overweight, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.